Paper Details

  1. Home
  2. Paper Details

Symposium on infectious complications of neoplastic disease (Part II). Chemoprophylaxis of bacterial infections in granulocytopenic patients.

Author: HenryS A

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Overview

Prophylactic oral nonabsorbable antibiotics may reduce the risk of infection in granulocytopenic patients, but side effects like nausea and vomiting can limit their use. Discontinuation of therapy during neutropenia is associated with life-threatening infections. The benefit of selective decontamination with trimethoprim/sulfamethoxazole remains controversial and may lead to resistant organisms or prolonged neutropenia. These regimens are not indicated for neutropenia less than 3 weeks, and the risks need to be considered even for prolonged neutropenia.
Paper Details　
Original Abstract of the Article :
Several prospectively randomized trials have shown that the administration of prophylactic oral nonabsorbable antibiotics may be beneficial in decreasing the incidence of infection in granulocytopenic patients, whereas others have not. Intolerable nausea and vomiting have prevented the prolonged use...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/0002-9343(84)90289-4

データ提供：米国国立医学図書館（NLM）

Preventing Infections in Granulocytopenic Patients: A Balancing Act

Granulocytopenia, a condition characterized by low levels of white blood cells, significantly increases the risk of infections. This symposium delves into the complex issue of chemoprophylaxis, exploring the use of antibiotics to prevent bacterial infections in granulocytopenic patients. The discussion centers on the challenges and controversies surrounding prophylactic antibiotic use, weighing potential benefits against the risks of side effects and the development of antibiotic resistance. The symposium aims to provide a comprehensive overview of the current state of knowledge and clinical practice regarding chemoprophylaxis in granulocytopenic patients.

The Dilemma of Chemoprophylaxis: Benefits and Risks

The symposium highlights the complex dilemma surrounding chemoprophylaxis in granulocytopenic patients. While some studies have shown a reduction in infection rates with prophylactic antibiotics, others have reported conflicting results. The discussion centers on the need to carefully weigh the potential benefits of preventing infections against the risks of side effects, antibiotic resistance, and the potential for prolonging neutropenia. The symposium emphasizes the need for individualized approaches to chemoprophylaxis based on patient-specific factors and the potential for alternative strategies.

Protecting Patients: A Collaborative Approach

The symposium underscores the importance of a collaborative approach to managing infections in granulocytopenic patients. This involves careful consideration of the potential benefits and risks of chemoprophylaxis, ongoing monitoring of patients for signs of infection, and the development of alternative strategies to mitigate the risks of antibiotic resistance. The symposium highlights the need for a multidisciplinary approach involving healthcare professionals from various specialties to provide the best possible care for these vulnerable patients.

Dr. Camel's Conclusion

Just as a camel navigates the arid desert, healthcare professionals navigate the challenges of managing infections in granulocytopenic patients. This symposium offers a comprehensive overview of the current state of knowledge and clinical practice regarding chemoprophylaxis, highlighting the complex balance between potential benefits and risks. The key lies in finding the most effective and safe approach for each individual patient, ensuring their well-being while mitigating the potential for antibiotic resistance.

Date :
  1. Date Completed 1984-05-10
  2. Date Revised 2019-06-27
Further Info :

Pubmed ID

6369979

DOI: Digital Object Identifier

10.1016/0002-9343(84)90289-4

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.